Poliovirus type 1, 2, or 3 antigen

Poliovirus type 1, 2, and 3 antigens are capsid proteins exposed on the surface of the respective poliovirus virions (PV1, PV2, PV3), which serve as the primary targets for neutralizing antibodies and are used in vaccines to prevent poliomyelitis. These antigens are complex assemblies of the four structural viral proteins VP1, VP2, VP3, and VP4, which together constitute the icosahedral protective shell of the virus and define serotypic differences. Antibodies and vaccines targeting these antigens enable immune recognition and neutralization, preventing viral entry via the poliovirus receptor (CD155) and subsequent cellular infection[1][3][4][5]. The antigens are not themselves receptors or conventional molecular targets for drugs, but are critical determinants of immune protection and are central to vaccine design and efficacy testing. Clarification: - This submission is not a classic therapeutic target (receptor, enzyme, etc.), but rather a group of viral antigens—complex protein structures—used for immunological intervention, mainly vaccine development and serological monitoring. - The entry "Poliovirus types 1, 2, 3 antigens" should be split into three canonical antigen entries if rigorous molecular specificity is required, or re-cast as "Poliovirus capsid antigen (type 1/2/3)" for use in structured databases. - The actual therapeutic target for viral entry is human poliovirus receptor (CD155)[2], not the viral antigen itself. If you need information about the true host receptor target for poliovirus (CD155), which is a genuine therapeutic molecular target, please specify.

Other names

Poliovirus antigensPoliovirus type 1 antigenPoliovirus type 2 antigenPoliovirus type 3 antigenPV1 antigenPV2 antigenPV3 antigen

Vaccines induce neutralizing antibodies targeting the capsid antigens to prevent viral infection and systemic spread[3].